Guggenheim raised the price target for the Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock from “a Neutral” to “a Buy”. The rating was released on September 15, 2021. We previously noted in another research note published on August 05, 2021 by JP Morgan that upgraded the stock from an Underweight to a Neutral with a price target of $87 for SRPT stock. The research report from BTIG Research has initiated the stock to Buy, with a price target set at $110. The stock was resumed by Credit Suisse, who disclosed in a research note on April 26, 2021, to Neutral and set the price objective to $72. In their research brief published January 12, 2021, Citigroup analysts downgraded the Sarepta Therapeutics Inc. stock from Buy to Neutral with a price target of $108.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Sarepta Therapeutics Inc. (NASDAQ:SRPT) dipped -12.46% to close Wednesday’s market session at $83.22, lower as compared to yesterday’s close. The stock price fluctuated between $83.01 and $89.71 throughout the trading session with the volume trading being 2680831 shares, which represented a significant variation when compared to the three months average volume of 848.82K shares. The firm’s stock price fluctuated -14.45% within the last five trades and 3.66% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 14.58% in the last 6 months and 21.72% was added to its value over the previous 3 months. SRPT stock is trading at a margin of -8.86%, 0.03% and -0.85% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, SRPT deals in the Healthcare domain. The stock is trading -54.23 percent below its 52-week high and 27.44 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -1.66. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Sarepta Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $6.35 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 10.58 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 13.69, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.50 percent of Sarepta Therapeutics Inc. shares are owned by insiders, and 81.10 percent are held by financial institutions. BEHRENS M KATHLEEN, the Director at Sarepta Therapeutics Inc. (SRPT) has sold 5,000 shares of firm on Mar 10 at a price of $85.76 against the total amount of $0.43 million. In another inside trade, Wigzell Hans Lennart Rudolf, Director of Sarepta Therapeutics Inc. (NASDAQ:SRPT) sold 10,000 shares of the firm on Mar 08 for a total worth of $0.84 million at a price of $83.51. An inside trade which took place on Dec 11, Principal Financial Officer of Sarepta Therapeutics Inc. Bratica Joseph sold 1,115 shares of firm against total price of $0.18 million at the cost of $165.00 per share.